LUZHU BIOTECH-B (02480): Positive Clinical Data from Head-to-Head Comparison Study of LZ901-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

LUZHU BIOTECH-B (02480): Positive Clinical Data from Head-to-Head Comparison Study of LZ901

Stock News08-18

LUZHU BIOTECH-B (02480) announced that a randomized, active-controlled, non-inferiority trial comparing its core product LZ901 with the recombinant glycoprotein E (gE) subunit vaccine HZ/su (Shingrix®) has yielded positive immunogenicity and safety data in adults aged 50 and above.

The study enrolled 301 healthy adults aged 50 or older, with at least 291 healthy adults receiving two doses of either LZ901 or HZ/su vaccine. The research results demonstrated that compared to the HZ/su vaccine, LZ901 induced superior cellular immunogenicity and exhibited better safety profile in adults aged 50 and above.

LZ901 is a recombinant shingles vaccine independently developed by the Group and represents the company's core product, designed to prevent shingles and related complications (including postherpetic neuralgia) in adults aged 40 and above.

As of the announcement date, the biological product license application for LZ901 has been accepted by the National Medical Products Administration of the People's Republic of China and is currently under review.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

empty

No comments yet

Most Discussed

7x24

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1144104935?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-18 07:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144104935","market":"hk","top_or_hot":-1,"title":"LUZHU BIOTECH-B (02480): Positive Clinical Data from Head-to-Head Comparison Study of LZ901","media":"Stock News","content":"<p>LUZHU BIOTECH-B (02480) announced that a randomized, active-controlled, non-inferiority trial comparing its core product LZ901 with the recombinant glycoprotein E (gE) subunit vaccine HZ/su (Shingrix®) has yielded positive immunogenicity and safety data in adults aged 50 and above.</p>\n<p>The study enrolled 301 healthy adults aged 50 or older, with at least 291 healthy adults receiving two doses of either LZ901 or HZ/su vaccine. The research results demonstrated that compared to the HZ/su vaccine, LZ901 induced superior cellular immunogenicity and exhibited better safety profile in adults aged 50 and above.</p>\n<p>LZ901 is a recombinant shingles vaccine independently developed by the Group and represents the company's core product, designed to prevent shingles and related complications (including postherpetic neuralgia) in adults aged 40 and above.</p>\n<p>As of the announcement date, the biological product license application for LZ901 has been accepted by the National Medical Products Administration of the People's Republic of China and is currently under review.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LUZHU BIOTECH-B (02480): Positive Clinical Data from Head-to-Head Comparison Study of LZ901</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLUZHU BIOTECH-B (02480): Positive Clinical Data from Head-to-Head Comparison Study of LZ901\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-18 07:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LUZHU BIOTECH-B (02480) announced that a randomized, active-controlled, non-inferiority trial comparing its core product LZ901 with the recombinant glycoprotein E (gE) subunit vaccine HZ/su (Shingrix®) has yielded positive immunogenicity and safety data in adults aged 50 and above.</p>\n<p>The study enrolled 301 healthy adults aged 50 or older, with at least 291 healthy adults receiving two doses of either LZ901 or HZ/su vaccine. The research results demonstrated that compared to the HZ/su vaccine, LZ901 induced superior cellular immunogenicity and exhibited better safety profile in adults aged 50 and above.</p>\n<p>LZ901 is a recombinant shingles vaccine independently developed by the Group and represents the company's core product, designed to prevent shingles and related complications (including postherpetic neuralgia) in adults aged 40 and above.</p>\n<p>As of the announcement date, the biological product license application for LZ901 has been accepted by the National Medical Products Administration of the People's Republic of China and is currently under review.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02480","symbol_name":"绿竹生物-B","start_time":0,"source_url":"","article_id":"1144104935","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144104935","pubTimestamp":1755475094,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LUZHU BIOTECH-B (02480) announced that a randomized, active-controlled, non-inferiority trial comparing its core product LZ901 with the recombinant glycoprotein E (gE) subunit vaccine HZ/su...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02480":"绿竹生物-B","BK1161":"生物科技"},"translate_title":"露珠生物-B(02480)：LZ901头对头对比研究临床数据阳性","themeId":"2aff25c238125730bc7536591e12b53f","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02480":1},"content_text":"LUZHU BIOTECH-B (02480) announced that a randomized, active-controlled, non-inferiority trial comparing its core product LZ901 with the recombinant glycoprotein E (gE) subunit vaccine HZ/su (Shingrix®) has yielded positive immunogenicity and safety data in adults aged 50 and above.\nThe study enrolled 301 healthy adults aged 50 or older, with at least 291 healthy adults receiving two doses of either LZ901 or HZ/su vaccine. The research results demonstrated that compared to the HZ/su vaccine, LZ901 induced superior cellular immunogenicity and exhibited better safety profile in adults aged 50 and above.\nLZ901 is a recombinant shingles vaccine independently developed by the Group and represents the company's core product, designed to prevent shingles and related complications (including postherpetic neuralgia) in adults aged 40 and above.\nAs of the announcement date, the biological product license application for LZ901 has been accepted by the National Medical Products Administration of the People's Republic of China and is currently under review.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}